CincyTech-backed Eikonoklastes Therapeutics receives FDA approval for first-in-class ALS treatment
A Cincinnati-based biotech startup developing a first-in-class treatment for ALS is celebrating a key regulatory milestone, roughly two years after landing its first tranche of funding from Uptown-based investment firm CincyTech.
Eikonoklastes Therapeutics, a preclinical biotech company developing new drugs for neurodegenerative diseases and cancers, this week received U.S. Food and Drug Administration orphan drug designation for its ET-101 program.  According to the FDA, orphan drug designation…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Liz Engel Source Type: news
More News: Biotechnology | Brain | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Funding | Health Management | Neurology